(MENAFN- ProactiveInvestors)
() has raised a further $615000 after placing the final tranche of its Series B Convertible Notes to progress its AmpaSand™ Molecular Diagnostic platform.
The company has now raised a total of $2.5 million through the issue of 25000 Series B Notes.
These notes may be converted into shares at a conversion price of $0.25 each anytime from 1 May 2015 until 31st July 2015 representing a conversion premium of 19% to the pre-offer share price.
After 31st July 2015 the Notes may be converted at $0.23 per share. The Notes only pay interest in the event of redemption and are not redeemable by note holders until 31st December 2016.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.